Source case identification in HIV-exposed infants and tuberculosis diagnosis in an isoniazid prevention study

Int J Tuberc Lung Dis. 2016 Aug;20(8):1060-4. doi: 10.5588/ijtld.15.0602.

Abstract

Background: Identifying source cases of children exposed to tuberculosis (TB) is challenging. We examined the time-point of obtaining contact information of TB source cases in human immunodeficiency virus (HIV) infected and HIV-exposed uninfected (HEU) children in a randomised, placebo-controlled trial of pre-exposure to isoniazid prophylaxis.

Methods: A total of 543 HIV-infected and 808 HEU infants without TB exposure aged 3-4 months were enrolled between 2004 and 2008. At 3-monthly follow-up, infants were evaluated for TB and care givers were asked about new TB exposure.

Results: In total, 128 cases of TB disease and 40 deaths were recorded among 19% (105/543) of the HIV-infected and 8% (63/808) of the HEU children; 229 TB contact occasions were reported in 205/1351 (15%) children, of which 83% (189/229) were in the household. Of the 189 household contacts, 108 (53%) underwent microbiological evaluations; 81% (87/108) were positive. HIV-infected and HEU infants had similar frequencies of TB contact: in 48% of infants with definite TB, 58% with probable TB and 43% with possible TB. Of 128 children diagnosed with TB, a TB contact was identified for 59. Of these, 29/59 (49%) were identified at or after the child's TB diagnosis.

Conclusion: TB source cases are often identified at or after a child's TB diagnosis. More effort is required for earlier detection.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Age Factors
  • Antitubercular Agents / administration & dosage*
  • Antitubercular Agents / adverse effects
  • Coinfection*
  • Early Diagnosis
  • Female
  • HIV Infections / diagnosis
  • HIV Infections / epidemiology*
  • HIV Infections / mortality
  • Humans
  • Infant
  • Isoniazid / administration & dosage*
  • Isoniazid / adverse effects
  • Male
  • Prevalence
  • Primary Prevention*
  • Risk Factors
  • South Africa
  • Time Factors
  • Treatment Outcome
  • Tuberculosis, Pulmonary / diagnosis
  • Tuberculosis, Pulmonary / mortality
  • Tuberculosis, Pulmonary / prevention & control*
  • Tuberculosis, Pulmonary / transmission

Substances

  • Antitubercular Agents
  • Isoniazid